Dr. John C. Byrd, MD

Director, UPMC Hillman Cancer Center · University of Pittsburgh

The physician-scientist whose clinical trials established BTK inhibitors as the standard of care for CLL.

For Your Mom's Case

Byrd is a fundamentally different profile from Scheinberg. Where Scheinberg's work is experimental/backup, Byrd's work IS the treatment your mom is likely headed toward. His pivotal clinical trials are the reason ibrutinib and acalabrutinib exist as FDA-approved CLL drugs. Most content here is directly relevant — you'll see more amber than gray.

Mom's diagnosis
CLL/SLL — confirmed by surgical pathology (S26-09464, Apr 2026). No Richter transformation.
Pathology update
Bilateral tonsillectomy (2026-04-06): SLL involving both tonsils. Actinomyces in left tonsil crypts explains the "black" appearance. Ki-67 15–20% (higher than quiescent CLL — worth raising). CD49d-negative, dim CD38 (favorable).
Still needed
IGHV, TP53, 17p deletion, complex karyotype, staging imaging.
Likely treatment
Acalabrutinib + venetoclax (A+V), 14-month fixed-duration — per Feb 20, 2026 FDA approval. Byrd's work is why acalabrutinib exists and why it was chosen over ibrutinib for this combination.
His location
UPMC Hillman Cancer Center, Pittsburgh, PA (not NYC / MSK)
Color coding: highlighted passages directly apply to her CLL case. muted passages describe his AML or non-CLL work.

At a Glance

Role
Both clinical and research — physician-scientist. Board-certified hematologist who sees CLL patients.
Current position
Director, UPMC Hillman Cancer Center; Associate Vice Chancellor for Cancer Affairs; Hillman Professor of Oncology, University of Pittsburgh (effective Nov 2025)
Specialty
CLL and AML — two decades of clinical drug development. CLL is his primary clinical identity.
Location
5150 Centre Ave, Floor 5, Pittsburgh, PA 15232
Phone
412-623-3205
Board certifications
Internal Medicine · Hematology (ABIM)
Training
BA Chemistry (with distinction), Hendrix College · MD, University of Arkansas · Residency + Fellowship: Walter Reed Army Medical Center · Postdoc: Johns Hopkins
Track record
700+ papers · ~85,000+ citations · 23 patents · work contributed to 7 FDA-approved drugs · founded 2 therapeutics companies · mentored 90+ trainees
Recognition
ASH William Dameshek Prize (2015) — "revolutionized how CLL is viewed and treated" · AACR Burchenal Award (2016) · LLS Return of the Child Award (2016) · Blood Cancer United Excellence in Scientific Service (2025)
Key difference from the Scheinberg brief: Scheinberg's lab develops experimental therapies mostly for AML. Byrd's clinical trials produced the FDA-approved, standard-of-care drugs your mom will almost certainly take. If Scheinberg is the frontier, Byrd is the foundation.

Clinical Role

Byrd is a board-certified hematologist who has actively treated CLL patients throughout his career. His clinical experience is not incidental to his research — it drives it. He entered patients onto his own clinical trials and has described seeing his research transform outcomes in his own patient panel.

He trained at Walter Reed Army Medical Center (residency + fellowship), meaning he came through the military medical system before joining academic medicine. He then did a translational lab postdoc at Johns Hopkins before his 20-year tenure at Ohio State.

What he treats

Career Arc

YearsPositionSignificance
1991–1997 Walter Reed Army Medical Center Residency (Internal Medicine) + Fellowship (Hematology/Oncology). Military physician.
~1997–2001 Johns Hopkins Postdoctoral translational laboratory fellowship. Bridged clinical training with bench research.
2001–2021 Ohio State University 20-year tenure. Distinguished University Professor. D. Warren Brown Chair of Leukemia Research. Founding Director, Division of Hematology. Senior Advisor for Cancer Experimental Therapeutics at OSUCCC-James. This is where ibrutinib and acalabrutinib trials happened.
2021–2025 University of Cincinnati Gordon and Helen Hughes Taylor Professor. Chair, Department of Internal Medicine. Chief of Internal Medicine, UC Health. Built a comprehensive blood cancer center.
Nov 2025–present UPMC Hillman Cancer Center / University of Pittsburgh Director of one of the nation's premier NCI-Designated Comprehensive Cancer Centers. Associate Vice Chancellor for Cancer Affairs. Hillman Professor of Oncology. Current position.
Why the career arc matters: Each move was upward — from military physician to building a world-class CLL program at Ohio State, to chairing an entire department of medicine, to now running one of the top cancer centers in the US. The UPMC Hillman directorship (Nov 2025) is very recent and means he now has institutional authority over the entire cancer research and clinical enterprise there.

Research Focus

Byrd's career is organized around one central question: how do you replace chemotherapy for blood cancers with targeted drugs that work better and hurt less? His answer has been BTK inhibitors — and the clinical trials to prove they work.

1 Core — Mom's treatment

BTK inhibitor development

Byrd ran the pivotal trials for both major BTK inhibitors:

  • Ibrutinib (Imbruvica) — first-in-class. Byrd was lead investigator on the foundational NEJM 2013 paper and the Phase 3 RESONATE trial (NEJM 2014). FDA-approved 2014 for CLL.
  • Acalabrutinib (Calquence) — second-gen. Byrd led Phase 1/2 (NEJM 2016), the ELEVATE-RR head-to-head vs ibrutinib (JCO 2021). FDA-approved 2017 for CLL.

The acalabrutinib + venetoclax combination approved Feb 2026 uses Byrd's drug. Acalabrutinib was chosen over ibrutinib for this combination in part because of the ELEVATE-RR data Byrd generated showing equivalent efficacy with fewer cardiac side effects — critical for a fixed-duration combo where tolerability matters.

2 Relevant

BTK inhibitor resistance & next-gen strategies

What happens when CLL becomes resistant to ibrutinib or acalabrutinib? Byrd's lab studies the molecular mechanisms of BTK inhibitor resistance — particularly mutations in BTK itself (like C481S) that escape covalent inhibitors. This work feeds into the development of drugs like pirtobrutinib, which work through a different binding mechanism.

He is also exploring combination strategies — e.g., adding ianalumab to ibrutinib (Phase Ib results published Dec 2025) to deepen responses and potentially allow treatment discontinuation.

3

CLL biology & single-cell analysis

Byrd's most recent CLL work (May 2026, Clinical Cancer Research) uses single-cell RNA-seq to characterize how ibrutinib changes the tumor and immune microenvironment in CLL patients. This kind of work answers: why does the drug work for some patients and not others? and what does the immune system look like under treatment?

4

AML drug development

Byrd has a secondary research program in AML, focused on genomic characterization of mutations (NPM1, PTPN11, BRAF, IDH2) and clinical trials of targeted agents (anti-CD33 antibodies, menin inhibitors, hypomethylating agents). This work is less relevant to your mom's CLL but reflects his broad expertise in blood cancer drug development.

Top / Landmark Papers

These are the papers that changed CLL treatment. Ordered by field impact:

  1. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. Byrd JC, Furman RR, Coutre SE, et al. New England Journal of Medicine. 2013;369:32–42. Foundational THE ibrutinib paper. Phase 1b/2, first-in-class. Proved a pill could replace chemo for CLL. One of the most cited hematology papers of the decade.
  2. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. Byrd JC, Brown JR, O'Brien S, et al. New England Journal of Medicine. 2014;371:213–23. RESONATE Phase 3 randomized trial. Ibrutinib vs. ofatumumab in relapsed CLL. Showed superior PFS and OS. Led to full FDA approval.
  3. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. Byrd JC, Harrington B, O'Brien S, et al. New England Journal of Medicine. 2016;374:323–32. Acalabrutinib first-in-human Phase 1/2 of the second-gen BTK-i. Showed same efficacy with better selectivity. This drug is the "A" in the A+V combo your mom would get.
  4. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. Burger JA, Tedeschi A, Barr PM, ..., Byrd JC, et al. New England Journal of Medicine. 2015;373:2425–37. RESONATE-2 First-line ibrutinib vs. chlorambucil in older CLL patients. Proved BTK-i works as front-line, not just relapse.
  5. Acalabrutinib versus ibrutinib in previously treated CLL: results of the first randomized Phase III trial. Byrd JC, Hillmen P, Ghia P, et al. Journal of Clinical Oncology. 2021;39(31):3441–52. ELEVATE-RR Head-to-head BTK-i comparison. Acalabrutinib non-inferior with fewer cardiac side effects. This data is WHY acalabrutinib was chosen over ibrutinib for the A+V combination.
  6. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. Woyach JA, Ruppert AS, ..., Byrd JC. New England Journal of Medicine. 2018;379:2517–28. A041202 trial. Byrd as senior author. Proved ibrutinib-based regimens beat chemo in first-line older CLL.
  7. Three-year follow-up of treatment-naive and previously treated patients with CLL receiving single-agent ibrutinib. Byrd JC, et al. Blood. 2015;125:2497–506. Long-term durability data. Showed ibrutinib responses are durable, not just temporary.
  8. Ibrutinib treatment for first-line and relapsed/refractory CLL: final analysis of PCYC-1102. Byrd JC, et al. Clinical Cancer Research. 2020;26:3918–27. Up to 8 years follow-up — longest single-agent BTK-i data ever reported.
Pattern to notice: Four NEJM first-author papers on a single drug class for a single disease. That level of concentration in the top clinical journal is extremely unusual and reflects how central Byrd was to the entire BTK-inhibitor era of CLL. He didn't contribute to ibrutinib and acalabrutinib — he was the person who proved they worked.

Most Recent Papers (2025 – Early 2026)

Still publishing actively at UPMC Hillman. Mix of CLL (ibrutinib biology, acalabrutinib long-term data) and AML (genomics, drug development). CLL papers highlighted.

DateTitleJournal
May 2026 Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in CLL Treated with Ibrutinib Clin Cancer Res
Apr 2026 Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in untreated older AML Haematologica
Apr 2026 Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution Blood
Mar 2026 Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory CLL Blood Advances
Feb 2026 Characterization of PTPN11 mutations in acute myeloid leukemia JCI Insight
Dec 2025 Addition of ianalumab (VAY736) to ibrutinib in CLL: results from a Phase Ib study Clin Cancer Res
Nov 2025 IDH2 mutation associated with favorable outcome in older AML with HMA therapy Haematologica
The March 2026 acalabrutinib paper is directly relevant. This is the final Phase 2 data — long-term outcomes of the very drug your mom is likely to receive. This kind of extended follow-up data is what clinicians use to set expectations for durability.

FDA-Approved Drugs From His Work

This is the key inversion from the Scheinberg brief. While Scheinberg's therapies are all experimental, Byrd's clinical trial work directly contributed to 7 FDA-approved drugs. He didn't invent all the molecules in a lab — his role was running the human trials that proved they work, which is what the FDA requires for approval. No trial data, no approval.
DrugWhat it doesByrd's roleStatus
Ibrutinib
(Imbruvica)		 First-gen BTK inhibitor Lead investigator — PCYC-1102 (Phase 1b/2) and RESONATE (Phase 3). His data was the basis for FDA approval. FDA-approved 2014
Acalabrutinib
(Calquence)		 Second-gen BTK inhibitor Led Phase 1/2 first-in-human trial and ELEVATE-RR (Phase 3 head-to-head vs ibrutinib). Data supported CLL approval. FDA-approved 2017 (CLL)
Idelalisib
(Zydelig)		 PI3K-delta inhibitor Clinical trial involvement supporting CLL indication FDA-approved 2014
Rituximab
(Rituxan)		 Anti-CD20 antibody Combination studies in CLL establishing utility FDA-approved (CLL indication)
Alemtuzumab
(Campath)		 Anti-CD52 antibody Clinical studies in CLL FDA-approved

Note: His profile states 7 FDA-approved drugs; the remaining 2 may include additional CLL or AML indications. The ibrutinib and acalabrutinib contributions are the most directly attributable and the most relevant to your mom's case.

Direct lineage to Mom's likely regimen

The path from Byrd's work to your mom's treatment:
  1. 2013: Byrd proves ibrutinib works in CLL (NEJM). BTK inhibitors are born.
  2. 2016: Byrd proves acalabrutinib works in CLL (NEJM). Second-gen is validated.
  3. 2021: Byrd's ELEVATE-RR proves acalabrutinib equals ibrutinib with fewer cardiac toxicities. Acalabrutinib becomes the preferred BTK-i for combinations.
  4. 2025: AMPLIFY trial (different investigators) proves acalabrutinib + venetoclax beats chemo (NEJM).
  5. Feb 2026: FDA approves acalabrutinib + venetoclax as first-line CLL therapy.
  6. 2026: Your mom's oncologist prescribes the regimen.

Steps 1–3 are Byrd's direct work. Steps 4–6 build on it. Without his trials, neither ibrutinib nor acalabrutinib would be approved, and the A+V combination would not exist.

Bottom Line

John Byrd is the clinical trialist whose work is most directly responsible for the BTK inhibitor revolution in CLL. He didn't just contribute — his name is on the first-author line of the NEJM papers that launched both ibrutinib and acalabrutinib. This is the person who proved pills could replace chemo for CLL.

For your mom: the acalabrutinib in her likely A+V regimen exists as an FDA-approved drug because of his trials. His ELEVATE-RR data is why acalabrutinib (not ibrutinib) was selected for the AMPLIFY combination. He is not backup or experimental — he is the foundation.

He now directs UPMC Hillman Cancer Center in Pittsburgh. If you consider a second opinion or consult outside of University of Kentucky, he is one of the top CLL clinician-scientists in the world, and he's a clinician who actually sees patients — not solely a bench researcher.

Scheinberg vs. Byrd in one sentence: Scheinberg is frontier immunotherapy for when standard treatment fails; Byrd is the person who built the standard treatment.

Sources